Introduction

Mitral stenosis is quite uncommon in Western countries, yet it still is a frequent problem worldwide, particularly in developing countries. The low incidence in the United States, in particular, is largely because rheumatic fever resulting in rheumatic heart disease has been largely eradicated; nevertheless, occasional outbreaks do occur. The occurrence of rheumatic fever in Utah in the mid-1980s and early 1990s is notable.^1,2 That particular outbreak had two unusual aspects. First, as opposed to previous history of outbreaks typically appearing in lower socioeconomic groups, this outbreak seemed to affect the middle class. Second, there was a distressingly low incidence of a symptomatic streptococcal infection in the group developing rheumatic fever.

Rheumatic heart disease preferentially affects the mitral valve, with the order of involvement being (1) mitral, (2) aortic, (3) tricuspid, and (4) pulmonic. The mitral valve is involved in virtually all cases, whereas the aortic valve is affected in 20% to 25% of cases. Pulmonary valve involvement in rheumatic heart disease is exceedingly rare. Even though the tricuspid valve frequently is involved, tricuspid valvular disease often is clinically silent.³ From a functional standpoint, however, approximately 25% of patients with rheumatic heart disease have pure mitral stenosis and 40% have a combination of mitral stenosis and mitral regurgitation.⁴ Two thirds of all patients with rheumatic mitral stenosis are female⁵; however, in my experience, it is almost 90%. In the United States and other Western countries, mitral stenosis develops over a period of decades, with a mean age of onset of 45 years. However, for reasons that are not entirely understood, individuals in developing countries such as India, in Africa, and in Alaskan Inuits, the time from rheumatic fever to onset of clinically significant mitral stenosis can be as little as 10 years. The factors for this rapid onset, however, appear to be more socioeconomic than necessarily related to specific medical care.^6,7

Cardiac Imaging and Real-Time Three-Dimensional Echocardiography

From the standpoint of cardiac imaging, echocardiography is clearly the mainstay for evaluation of mitral stenosis. The extent of mitral valvular deformity traditionally has been evaluated by two-dimensional (2D) echocardiography and graded based on a score of 0 to 4 for each of four factors: (1) valvular thickening, (2) valvular mobility, (3) degree of leaflet calcification, and (4) extent of subvalvular thickening and calcification.⁸ The Wilkins scoring system does have several drawbacks, however. In particular, some patients with a high Wilkins score still respond well to percutaneous mitral valvuloplasty (PMV). Three-dimensional (3D) echocardiography provides incremental information regarding the status of rheumatic involvement of the mitral valve, particularly regarding the fusion of the commissures. Determination of the status of commissural fusion, particularly the symmetry and length of commissural fusion, is critical information to predict the success of treatment of mitral stenosis with PMV.⁹ That is, mitral valvuloplasty is most effective when extensive symmetric commissural fusion is present and when such fusion is alleviated at the time of the procedure. 3D echocardiography (3DE) has a particular strength for visualizing the mitral commissures and commissural fusion because of the added dimension of elevation (Figures 6-1 to 6-5; Videos 6-1 to 6-9). The elevation dimension allows clearer assessment of the degree and length of commissural fusion as well as the presence of structures that could inhibit the process, such as rheumatic nodules and subvalvular (typically chordal) thickening. Although in mitral stenosis symmetric commissural fusion is the optimal morphology for PMV success, evidence indicates that if the commissural fusion is accompanied by significant calcification, results are not as satisfactory, which is a predictable finding.^10–12

Figure 6-1 A and B, Two-dimensional (2D) and three-dimensional (3D) parasternal long-axis views of the mitral valve in a patient with mitral stenosis. Both show the characteristic “doming” or “hockey stick” appearance of the anterior mitral valve leaflet (arrow). The 3D details the subvalvular apparatus not appreciated on the 2D image (see Videos 6-1 and 6-2).

Figure 6-2 Two-dimensional (A) and three-dimensional (3D) (B) short-axis views of mitral stenosis. Both images show bilateral commissural fusion, with the lateral commissure more fused than the medial commissure. The 3D image allows superior visualization of the thickening of the mitral leaflets, particularly the commissures.

Figure 6-3 A, QLAB (Phillips Healthcare, Andover, MA) evaluation of the mitral valve area. This is the first step in using a transthoracic three-dimensional (3D) full-volume acquisition of the mitral valve to quantify the degree of mitral stenosis by measuring the mitral valve area. This is the starting point, with the full volume acquired and initial autocropping performed automatically by the software. The autocropping shows the mitral valve in the parasternal long-axis view. Here, the parasternal long-axis view has been acquired in full-volume mode and has been stored to an Xcelera (Phillips Healthcare) page. From here, the operator activates the QLAB icon (pyramid) to move into the cropping function and the 3DQ quantification package. B, Quantification step 2. The operator is now within the QLAB software. This particular view shows the full volume within QLAB, with the crop box turned off. From here, the operator enters the 3DQ quantification package. C, Quantification step 3 is the multiplanar reconstruction mode of QLAB. Here, the mitral valve is shown in parasternal long axis (upper left), parasternal short axis (upper right), a composite (lower left), and the entire volume of the heart (lower right). Placing the red plane cursor so the mitral valve is cut in cross-section (upper right) at the very tip of the mitral valve leaflets allows the mitral valve area to be measured at the most optimal angle. D, Quantification step 4. Here, the red plane is positioned at the tips of the mitral leaflets (upper left) so that the operator can be certain that the orifice is in the true en face view in the upper right plane. The lower right image is a view of the entire volume that can be manipulated to see how the red plane is being moved relative to the entire mitral valve apparatus. E, Quantification final step. The mitral valve area is traced, resulting in a mitral valve area of 1.86 cm in this case.

Figure 6-4 A, Two-dimensional (2D) transthoracic image of mitral stenosis. Note the marked thickening of the anterior mitral leaflet. B, The same patient as viewed by parasternal three-dimensional (3D) transthoracic echocardiography from the left ventricular side of the valve. Note the rheumatic nodules that are noted by 3D echocardiography that were not appreciated in 2D. Also note the details of commissural fusion shown in this swivel display and the asymmetric fusion of the commissures. The same patient viewed from the left atrial side (C) and ventricular side (D) with a slight tilt toward the anterior leaflet so that the extensive rheumatic disease, accentuated by the nodules (arrow), is seen (see Videos 6-6 to 6-9).

Figure 6-5 A patient 3 years after percutaneous mitral valvuloplasty. The splitting of the commissures is seen on both sides (arrows). In this case, the lateral commissure is more open; the three-dimensional view shows this in more detail (see Video 6-5).

Mitral Valve Area Determination